Leidos director granted shares and stock options

Leidos Holdings director Nancy A. Norton reported new equity awards.

Rhea-AI Filing Summary

Leidos Holdings director Nancy A. Norton reported new equity awards. On May 8, 2026, she received 1,067 shares of Leidos common stock as a stock award at no cash cost, increasing her direct holdings to 3,144 shares.

She was also granted stock options for 1,281 shares of common stock with an exercise price of $131.26 per share. According to the footnote, these options vest and become exercisable in full on the earlier of the first anniversary of the grant date or the date the next annual meeting of stockholders is concluded, and they expire on May 7, 2033.

Insider Trade Summary

Grant/Award: 2,348 shares

Grant/Award 2 txns

Insider Norton Nancy A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,281	$0.00	$0.00
Grant/Award	Common Stock	1,067	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,281 contracts (Direct); Common Stock — 3,144 shares (Direct)

Footnotes (1)

1. F1. The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded.

Key Figures

Common stock award: 1,067 shares Shares held after award: 3,144 shares Stock options granted: 1,281 options +3 more

6 metrics

Common stock award 1,067 shares Granted on May 8, 2026 as equity award

Shares held after award 3,144 shares Direct common stock holdings after grant

Stock options granted 1,281 options Right to buy common stock granted May 8, 2026

Option exercise price $131.26 per share Conversion or exercise price for options

Option vesting trigger Earlier of 1-year or next AGM Vests on first anniversary of grant or next annual meeting conclusion

Option expiration date May 7, 2033 Final date to exercise granted stock options

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "131.2600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option shall vest and become exercisable in full on the earlier of..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the stockholders financial

"the date that the next annual meeting of the stockholders of the Company is concluded"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Leidos (LDOS) director Nancy A. Norton report in this Form 4?

Nancy A. Norton reported receiving equity compensation from Leidos Holdings. She was granted 1,067 shares of common stock and stock options for 1,281 shares, both recorded as awards rather than open-market purchases or sales.

How many Leidos (LDOS) shares does Nancy A. Norton now hold directly?

After the reported award, Nancy A. Norton directly holds 3,144 shares of Leidos common stock. This figure reflects her position following the grant of 1,067 new shares recorded on May 8, 2026, as disclosed in the Form 4 filing.

What are the key terms of Nancy A. Norton’s Leidos (LDOS) stock options?

Nancy A. Norton received options on 1,281 Leidos shares with a $131.26 exercise price. The options vest in full on the earlier of the first anniversary of the grant date or the conclusion of the next annual stockholders’ meeting and expire on May 7, 2033.

Is Nancy A. Norton’s Leidos (LDOS) Form 4 a market buy or sell?

The Form 4 reflects compensation awards, not market trades. Both the 1,067 common shares and 1,281 stock options were recorded with transaction code A, indicating grants or awards, with no open-market buying or selling reported in this filing.

When do Nancy A. Norton’s Leidos (LDOS) stock options become exercisable?

The options vest and become exercisable in full on the earlier of the first anniversary of the grant date or the date the next annual stockholders’ meeting concludes. This single-vesting structure links exercisability to either time passage or the next shareholder meeting.

What is the expiration date of Nancy A. Norton’s Leidos (LDOS) stock options?

The stock options granted to Nancy A. Norton expire on May 7, 2033. After that date, any unexercised options become worthless, so the exercisability window runs from vesting until this expiration date as specified in the Form 4 disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 08:55 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norton Nancy A

(Last) (First) (Middle)

1750 PRESIDENTS STREET

(Street)

RESTON VIRGINIA 20190

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Leidos Holdings, Inc. [ LDOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		A		1,067	A	$0	3,144	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$131.26	05/08/2026		A		1,281		05/08/2027(1)	05/07/2033	Common Stock	1,281	$0	1,281	D

Explanation of Responses:

1. The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded.

Remarks:

	/s/ Ramune M. Kligys by PoA of Nancy A. Norton	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)